Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin
about
Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in MiceUtility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityChemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in ratsMechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Pharmacokinetics of doxorubicin in pregnant women.Cardiotoxicity of anticancer treatments.The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity.Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells.The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte.
P2860
Q27345163-9E586024-9A13-4C5E-865D-877D2086CC03Q28301317-65216F24-2850-48F5-9DC5-F637886166B2Q34659375-E1EF2233-509D-4A82-9176-27C0AB3A37C0Q35044266-A6595436-6057-472C-A1DA-5FD0B05BA9CCQ36053116-67214DAD-4C1A-4736-8388-895728E2BE69Q36559677-DF6963B7-B5E3-42C5-8DB5-E0473566A238Q36568908-BF78F5FB-9D72-4B24-91A3-13574D527B20Q37695910-E479D63C-2F02-4591-BA95-BD78258C4B79Q38473331-8421BFFF-1109-455F-BE38-EF0359811F85Q38927458-60912567-32A3-4CB9-87D8-B3B306BECAF6Q40558168-497D1DDF-A999-482C-A307-0B6DDDB3DD06Q43495742-8B0CAA95-893B-44A0-A9B3-0CEF5EF1B14AQ44312601-53F39D1E-8756-4DAE-978B-5ECBE2A8D469Q46770269-B5CBC88A-CAF3-47B5-9B2D-5E14C849311BQ48170012-6E92A60E-090A-4FBE-A39E-C2D7E4E41941Q54022874-3285F158-E881-438B-9D9E-C29CF062C790
P2860
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@ast
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@en
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@nl
type
label
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@ast
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@en
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@nl
prefLabel
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@ast
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@en
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@nl
P2093
P356
P1476
Pharmacokinetics of the cardio ...... ed with fixed-dose doxorubicin
@en
P2093
H Hochster
J L Speyer
P304
P356
10.1093/JNCI/84.22.1725
P407
P577
1992-11-18T00:00:00Z